Global Male Hypogonadism Therapy Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 281288
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Male Hypogonadism Therapy market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Male Hypogonadism Therapy market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Male Hypogonadism Therapy global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Parenteral segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Male Hypogonadism Therapy include Eli Lilly, Pfizer, AbbVie, Novo Nordisk, and Merck KGaA, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Male Hypogonadism Therapy market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Parenteral

Transdermal

Oral

Others

Market segment by Application, can be divided into

Hospitals

Drugstores

Others

Market segment by players, this report covers

Eli Lilly

Pfizer

AbbVie

Novo Nordisk

Merck KGaA

Mylan

Bayer

Teva

Novartis

Abbott

Roche

Endo International

Ipsen

ANI Pharmaceuticals

TherapeuticsMD

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Male Hypogonadism Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Male Hypogonadism Therapy, with revenue, gross margin and global market share of Male Hypogonadism Therapy from 2019 to 2022.

Chapter 3, the Male Hypogonadism Therapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Male Hypogonadism Therapy market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Male Hypogonadism Therapy research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1 Market Overview

1.1 Product Overview and Scope of Male Hypogonadism Therapy

1.2 Classification of Male Hypogonadism Therapy by Type

1.2.1 Overview: Global Male Hypogonadism Therapy Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Male Hypogonadism Therapy Revenue Market Share by Type in 2021

1.2.3 Parenteral

1.2.4 Transdermal

1.2.5 Oral

1.2.6 Others

1.3 Global Male Hypogonadism Therapy Market by Application

1.3.1 Overview: Global Male Hypogonadism Therapy Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospitals

1.3.3 Drugstores

1.3.4 Others

1.4 Global Male Hypogonadism Therapy Market Size & Forecast

1.5 Global Male Hypogonadism Therapy Market Size and Forecast by Region

1.5.1 Global Male Hypogonadism Therapy Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Male Hypogonadism Therapy Market Size by Region, (2017-2022)

1.5.3 North America Male Hypogonadism Therapy Market Size and Prospect (2017-2028)

1.5.4 Europe Male Hypogonadism Therapy Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Male Hypogonadism Therapy Market Size and Prospect (2017-2028)

1.5.6 South America Male Hypogonadism Therapy Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Male Hypogonadism Therapy Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Male Hypogonadism Therapy Market Drivers

1.6.2 Male Hypogonadism Therapy Market Restraints

1.6.3 Male Hypogonadism Therapy Trends Analysis

2 Company Profiles

2 Company Profiles

2.1 Eli Lilly

2.1.1 Eli Lilly Details

2.1.2 Eli Lilly Major Business

2.1.3 Eli Lilly Male Hypogonadism Therapy Product and Solutions

2.1.4 Eli Lilly Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Eli Lilly Recent Developments and Future Plans

2.2 Pfizer

2.2.1 Pfizer Details

2.2.2 Pfizer Major Business

2.2.3 Pfizer Male Hypogonadism Therapy Product and Solutions

2.2.4 Pfizer Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Pfizer Recent Developments and Future Plans

2.3 AbbVie

2.3.1 AbbVie Details

2.3.2 AbbVie Major Business

2.3.3 AbbVie Male Hypogonadism Therapy Product and Solutions

2.3.4 AbbVie Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 AbbVie Recent Developments and Future Plans

2.4 Novo Nordisk

2.4.1 Novo Nordisk Details

2.4.2 Novo Nordisk Major Business

2.4.3 Novo Nordisk Male Hypogonadism Therapy Product and Solutions

2.4.4 Novo Nordisk Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Novo Nordisk Recent Developments and Future Plans

2.5 Merck KGaA

2.5.1 Merck KGaA Details

2.5.2 Merck KGaA Major Business

2.5.3 Merck KGaA Male Hypogonadism Therapy Product and Solutions

2.5.4 Merck KGaA Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Merck KGaA Recent Developments and Future Plans

2.6 Mylan

2.6.1 Mylan Details

2.6.2 Mylan Major Business

2.6.3 Mylan Male Hypogonadism Therapy Product and Solutions

2.6.4 Mylan Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Mylan Recent Developments and Future Plans

2.7 Bayer

2.7.1 Bayer Details

2.7.2 Bayer Major Business

2.7.3 Bayer Male Hypogonadism Therapy Product and Solutions

2.7.4 Bayer Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Bayer Recent Developments and Future Plans

2.8 Teva

2.8.1 Teva Details

2.8.2 Teva Major Business

2.8.3 Teva Male Hypogonadism Therapy Product and Solutions

2.8.4 Teva Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Teva Recent Developments and Future Plans

2.9 Novartis

2.9.1 Novartis Details

2.9.2 Novartis Major Business

2.9.3 Novartis Male Hypogonadism Therapy Product and Solutions

2.9.4 Novartis Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Novartis Recent Developments and Future Plans

2.10 Abbott

2.10.1 Abbott Details

2.10.2 Abbott Major Business

2.10.3 Abbott Male Hypogonadism Therapy Product and Solutions

2.10.4 Abbott Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Abbott Recent Developments and Future Plans

2.11 Roche

2.11.1 Roche Details

2.11.2 Roche Major Business

2.11.3 Roche Male Hypogonadism Therapy Product and Solutions

2.11.4 Roche Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Roche Recent Developments and Future Plans

2.12 Endo International

2.12.1 Endo International Details

2.12.2 Endo International Major Business

2.12.3 Endo International Male Hypogonadism Therapy Product and Solutions

2.12.4 Endo International Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Endo International Recent Developments and Future Plans

2.13 Ipsen

2.13.1 Ipsen Details

2.13.2 Ipsen Major Business

2.13.3 Ipsen Male Hypogonadism Therapy Product and Solutions

2.13.4 Ipsen Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Ipsen Recent Developments and Future Plans

2.14 ANI Pharmaceuticals

2.14.1 ANI Pharmaceuticals Details

2.14.2 ANI Pharmaceuticals Major Business

2.14.3 ANI Pharmaceuticals Male Hypogonadism Therapy Product and Solutions

2.14.4 ANI Pharmaceuticals Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 ANI Pharmaceuticals Recent Developments and Future Plans

2.15 TherapeuticsMD

2.15.1 TherapeuticsMD Details

2.15.2 TherapeuticsMD Major Business

2.15.3 TherapeuticsMD Male Hypogonadism Therapy Product and Solutions

2.15.4 TherapeuticsMD Male Hypogonadism Therapy Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 TherapeuticsMD Recent Developments and Future Plans

3 Market Competition, by Players

3 Market Competition, by Players

3.1 Global Male Hypogonadism Therapy Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Male Hypogonadism Therapy Players Market Share in 2021

3.2.2 Top 10 Male Hypogonadism Therapy Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Male Hypogonadism Therapy Players Head Office, Products and Services Provided

3.4 Male Hypogonadism Therapy Mergers & Acquisitions

3.5 Male Hypogonadism Therapy New Entrants and Expansion Plans

4 Market Size Segment by Type

4 Market Size Segment by Type

4.1 Global Male Hypogonadism Therapy Revenue and Market Share by Type (2017-2022)

4.2 Global Male Hypogonadism Therapy Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5 Market Size Segment by Application

5.1 Global Male Hypogonadism Therapy Revenue Market Share by Application (2017-2022)

5.2 Global Male Hypogonadism Therapy Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6 North America by Country, by Type, and by Application

6.1 North America Male Hypogonadism Therapy Revenue by Type (2017-2028)

6.2 North America Male Hypogonadism Therapy Revenue by Application (2017-2028)

6.3 North America Male Hypogonadism Therapy Market Size by Country

6.3.1 North America Male Hypogonadism Therapy Revenue by Country (2017-2028)

6.3.2 United States Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

6.3.3 Canada Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

6.3.4 Mexico Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7 Europe by Country, by Type, and by Application

7.1 Europe Male Hypogonadism Therapy Revenue by Type (2017-2028)

7.2 Europe Male Hypogonadism Therapy Revenue by Application (2017-2028)

7.3 Europe Male Hypogonadism Therapy Market Size by Country

7.3.1 Europe Male Hypogonadism Therapy Revenue by Country (2017-2028)

7.3.2 Germany Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

7.3.3 France Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

7.3.5 Russia Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

7.3.6 Italy Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Male Hypogonadism Therapy Revenue by Type (2017-2028)

8.2 Asia-Pacific Male Hypogonadism Therapy Revenue by Application (2017-2028)

8.3 Asia-Pacific Male Hypogonadism Therapy Market Size by Region

8.3.1 Asia-Pacific Male Hypogonadism Therapy Revenue by Region (2017-2028)

8.3.2 China Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

8.3.3 Japan Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

8.3.4 South Korea Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

8.3.5 India Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

8.3.7 Australia Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9 South America by Country, by Type, and by Application

9.1 South America Male Hypogonadism Therapy Revenue by Type (2017-2028)

9.2 South America Male Hypogonadism Therapy Revenue by Application (2017-2028)

9.3 South America Male Hypogonadism Therapy Market Size by Country

9.3.1 South America Male Hypogonadism Therapy Revenue by Country (2017-2028)

9.3.2 Brazil Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

9.3.3 Argentina Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Male Hypogonadism Therapy Revenue by Type (2017-2028)

10.2 Middle East & Africa Male Hypogonadism Therapy Revenue by Application (2017-2028)

10.3 Middle East & Africa Male Hypogonadism Therapy Market Size by Country

10.3.1 Middle East & Africa Male Hypogonadism Therapy Revenue by Country (2017-2028)

10.3.2 Turkey Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

10.3.4 UAE Male Hypogonadism Therapy Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

11 Research Findings and Conclusion

12 Appendix

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Male Hypogonadism Therapy Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Male Hypogonadism Therapy Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Male Hypogonadism Therapy Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Male Hypogonadism Therapy Revenue (USD Million) by Region (2017-2022)

Table 5. Global Male Hypogonadism Therapy Revenue Market Share by Region (2023-2028)

Table 6. Eli Lilly Corporate Information, Head Office, and Major Competitors

Table 7. Eli Lilly Major Business

Table 8. Eli Lilly Male Hypogonadism Therapy Product and Solutions

Table 9. Eli Lilly Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Pfizer Corporate Information, Head Office, and Major Competitors

Table 11. Pfizer Major Business

Table 12. Pfizer Male Hypogonadism Therapy Product and Solutions

Table 13. Pfizer Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. AbbVie Corporate Information, Head Office, and Major Competitors

Table 15. AbbVie Major Business

Table 16. AbbVie Male Hypogonadism Therapy Product and Solutions

Table 17. AbbVie Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Novo Nordisk Corporate Information, Head Office, and Major Competitors

Table 19. Novo Nordisk Major Business

Table 20. Novo Nordisk Male Hypogonadism Therapy Product and Solutions

Table 21. Novo Nordisk Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Merck KGaA Corporate Information, Head Office, and Major Competitors

Table 23. Merck KGaA Major Business

Table 24. Merck KGaA Male Hypogonadism Therapy Product and Solutions

Table 25. Merck KGaA Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Mylan Corporate Information, Head Office, and Major Competitors

Table 27. Mylan Major Business

Table 28. Mylan Male Hypogonadism Therapy Product and Solutions

Table 29. Mylan Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Bayer Corporate Information, Head Office, and Major Competitors

Table 31. Bayer Major Business

Table 32. Bayer Male Hypogonadism Therapy Product and Solutions

Table 33. Bayer Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Teva Corporate Information, Head Office, and Major Competitors

Table 35. Teva Major Business

Table 36. Teva Male Hypogonadism Therapy Product and Solutions

Table 37. Teva Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Novartis Corporate Information, Head Office, and Major Competitors

Table 39. Novartis Major Business

Table 40. Novartis Male Hypogonadism Therapy Product and Solutions

Table 41. Novartis Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Abbott Corporate Information, Head Office, and Major Competitors

Table 43. Abbott Major Business

Table 44. Abbott Male Hypogonadism Therapy Product and Solutions

Table 45. Abbott Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Roche Corporate Information, Head Office, and Major Competitors

Table 47. Roche Major Business

Table 48. Roche Male Hypogonadism Therapy Product and Solutions

Table 49. Roche Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Endo International Corporate Information, Head Office, and Major Competitors

Table 51. Endo International Major Business

Table 52. Endo International Male Hypogonadism Therapy Product and Solutions

Table 53. Endo International Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Ipsen Corporate Information, Head Office, and Major Competitors

Table 55. Ipsen Major Business

Table 56. Ipsen Male Hypogonadism Therapy Product and Solutions

Table 57. Ipsen Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. ANI Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 59. ANI Pharmaceuticals Major Business

Table 60. ANI Pharmaceuticals Male Hypogonadism Therapy Product and Solutions

Table 61. ANI Pharmaceuticals Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. TherapeuticsMD Corporate Information, Head Office, and Major Competitors

Table 63. TherapeuticsMD Major Business

Table 64. TherapeuticsMD Male Hypogonadism Therapy Product and Solutions

Table 65. TherapeuticsMD Male Hypogonadism Therapy Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Global Male Hypogonadism Therapy Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 67. Global Male Hypogonadism Therapy Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 68. Breakdown of Male Hypogonadism Therapy by Company Type (Tier 1, Tier 2 and Tier 3)

Table 69. Male Hypogonadism Therapy Players Head Office, Products and Services Provided

Table 70. Male Hypogonadism Therapy Mergers & Acquisitions in the Past Five Years

Table 71. Male Hypogonadism Therapy New Entrants and Expansion Plans

Table 72. Global Male Hypogonadism Therapy Revenue (USD Million) by Type (2017-2022)

Table 73. Global Male Hypogonadism Therapy Revenue Share by Type (2017-2022)

Table 74. Global Male Hypogonadism Therapy Revenue Forecast by Type (2023-2028)

Table 75. Global Male Hypogonadism Therapy Revenue by Application (2017-2022)

Table 76. Global Male Hypogonadism Therapy Revenue Forecast by Application (2023-2028)

Table 77. North America Male Hypogonadism Therapy Revenue by Type (2017-2022) & (USD Million)

Table 78. North America Male Hypogonadism Therapy Revenue by Type (2023-2028) & (USD Million)

Table 79. North America Male Hypogonadism Therapy Revenue by Application (2017-2022) & (USD Million)

Table 80. North America Male Hypogonadism Therapy Revenue by Application (2023-2028) & (USD Million)

Table 81. North America Male Hypogonadism Therapy Revenue by Country (2017-2022) & (USD Million)

Table 82. North America Male Hypogonadism Therapy Revenue by Country (2023-2028) & (USD Million)

Table 83. Europe Male Hypogonadism Therapy Revenue by Type (2017-2022) & (USD Million)

Table 84. Europe Male Hypogonadism Therapy Revenue by Type (2023-2028) & (USD Million)

Table 85. Europe Male Hypogonadism Therapy Revenue by Application (2017-2022) & (USD Million)

Table 86. Europe Male Hypogonadism Therapy Revenue by Application (2023-2028) & (USD Million)

Table 87. Europe Male Hypogonadism Therapy Revenue by Country (2017-2022) & (USD Million)

Table 88. Europe Male Hypogonadism Therapy Revenue by Country (2023-2028) & (USD Million)

Table 89. Asia-Pacific Male Hypogonadism Therapy Revenue by Type (2017-2022) & (USD Million)

Table 90. Asia-Pacific Male Hypogonadism Therapy Revenue by Type (2023-2028) & (USD Million)

Table 91. Asia-Pacific Male Hypogonadism Therapy Revenue by Application (2017-2022) & (USD Million)

Table 92. Asia-Pacific Male Hypogonadism Therapy Revenue by Application (2023-2028) & (USD Million)

Table 93. Asia-Pacific Male Hypogonadism Therapy Revenue by Region (2017-2022) & (USD Million)

Table 94. Asia-Pacific Male Hypogonadism Therapy Revenue by Region (2023-2028) & (USD Million)

Table 95. South America Male Hypogonadism Therapy Revenue by Type (2017-2022) & (USD Million)

Table 96. South America Male Hypogonadism Therapy Revenue by Type (2023-2028) & (USD Million)

Table 97. South America Male Hypogonadism Therapy Revenue by Application (2017-2022) & (USD Million)

Table 98. South America Male Hypogonadism Therapy Revenue by Application (2023-2028) & (USD Million)

Table 99. South America Male Hypogonadism Therapy Revenue by Country (2017-2022) & (USD Million)

Table 100. South America Male Hypogonadism Therapy Revenue by Country (2023-2028) & (USD Million)

Table 101. Middle East & Africa Male Hypogonadism Therapy Revenue by Type (2017-2022) & (USD Million)

Table 102. Middle East & Africa Male Hypogonadism Therapy Revenue by Type (2023-2028) & (USD Million)

Table 103. Middle East & Africa Male Hypogonadism Therapy Revenue by Application (2017-2022) & (USD Million)

Table 104. Middle East & Africa Male Hypogonadism Therapy Revenue by Application (2023-2028) & (USD Million)

Table 105. Middle East & Africa Male Hypogonadism Therapy Revenue by Country (2017-2022) & (USD Million)

Table 106. Middle East & Africa Male Hypogonadism Therapy Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Male Hypogonadism Therapy Picture

Figure 2. Global Male Hypogonadism Therapy Revenue Market Share by Type in 2021

Figure 3. Parenteral

Figure 4. Transdermal

Figure 5. Oral

Figure 6. Others

Figure 7. Male Hypogonadism Therapy Revenue Market Share by Application in 2021

Figure 8. Hospitals Picture

Figure 9. Drugstores Picture

Figure 10. Others Picture

Figure 11. Global Male Hypogonadism Therapy Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 12. Global Male Hypogonadism Therapy Revenue and Forecast (2017-2028) & (USD Million)

Figure 13. Global Male Hypogonadism Therapy Revenue Market Share by Region (2017-2028)

Figure 14. Global Male Hypogonadism Therapy Revenue Market Share by Region in 2021

Figure 15. North America Male Hypogonadism Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Europe Male Hypogonadism Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Asia-Pacific Male Hypogonadism Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. South America Male Hypogonadism Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Middle East and Africa Male Hypogonadism Therapy Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Male Hypogonadism Therapy Market Drivers

Figure 21. Male Hypogonadism Therapy Market Restraints

Figure 22. Male Hypogonadism Therapy Market Trends

Figure 23. Eli Lilly Recent Developments and Future Plans

Figure 24. Pfizer Recent Developments and Future Plans

Figure 25. AbbVie Recent Developments and Future Plans

Figure 26. Novo Nordisk Recent Developments and Future Plans

Figure 27. Merck KGaA Recent Developments and Future Plans

Figure 28. Mylan Recent Developments and Future Plans

Figure 29. Bayer Recent Developments and Future Plans

Figure 30. Teva Recent Developments and Future Plans

Figure 31. Novartis Recent Developments and Future Plans

Figure 32. Abbott Recent Developments and Future Plans

Figure 33. Roche Recent Developments and Future Plans

Figure 34. Endo International Recent Developments and Future Plans

Figure 35. Ipsen Recent Developments and Future Plans

Figure 36. ANI Pharmaceuticals Recent Developments and Future Plans

Figure 37. TherapeuticsMD Recent Developments and Future Plans

Figure 38. Global Male Hypogonadism Therapy Revenue Share by Players in 2021

Figure 39. Male Hypogonadism Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 40. Global Top 3 Players Male Hypogonadism Therapy Revenue Market Share in 2021

Figure 41. Global Top 10 Players Male Hypogonadism Therapy Revenue Market Share in 2021

Figure 42. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 43. Global Male Hypogonadism Therapy Revenue Share by Type in 2021

Figure 44. Global Male Hypogonadism Therapy Market Share Forecast by Type (2023-2028)

Figure 45. Global Male Hypogonadism Therapy Revenue Share by Application in 2021

Figure 46. Global Male Hypogonadism Therapy Market Share Forecast by Application (2023-2028)

Figure 47. North America Male Hypogonadism Therapy Sales Market Share by Type (2017-2028)

Figure 48. North America Male Hypogonadism Therapy Sales Market Share by Application (2017-2028)

Figure 49. North America Male Hypogonadism Therapy Revenue Market Share by Country (2017-2028)

Figure 50. United States Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Canada Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Mexico Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Europe Male Hypogonadism Therapy Sales Market Share by Type (2017-2028)

Figure 54. Europe Male Hypogonadism Therapy Sales Market Share by Application (2017-2028)

Figure 55. Europe Male Hypogonadism Therapy Revenue Market Share by Country (2017-2028)

Figure 56. Germany Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. France Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. United Kingdom Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Russia Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Italy Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Asia-Pacific Male Hypogonadism Therapy Sales Market Share by Type (2017-2028)

Figure 62. Asia-Pacific Male Hypogonadism Therapy Sales Market Share by Application (2017-2028)

Figure 63. Asia-Pacific Male Hypogonadism Therapy Revenue Market Share by Region (2017-2028)

Figure 64. China Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Japan Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. South Korea Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. India Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. Southeast Asia Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Australia Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. South America Male Hypogonadism Therapy Sales Market Share by Type (2017-2028)

Figure 71. South America Male Hypogonadism Therapy Sales Market Share by Application (2017-2028)

Figure 72. South America Male Hypogonadism Therapy Revenue Market Share by Country (2017-2028)

Figure 73. Brazil Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 74. Argentina Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Middle East and Africa Male Hypogonadism Therapy Sales Market Share by Type (2017-2028)

Figure 76. Middle East and Africa Male Hypogonadism Therapy Sales Market Share by Application (2017-2028)

Figure 77. Middle East and Africa Male Hypogonadism Therapy Revenue Market Share by Country (2017-2028)

Figure 78. Turkey Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 79. Saudi Arabia Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. UAE Male Hypogonadism Therapy Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. Methodology

Figure 82. Research Process and Data Source